Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alisporivir - Debiopharm

Drug Profile

Alisporivir - Debiopharm

Alternative Names: DEB-025; DEBIO-025; DEBIO-25

Latest Information Update: 05 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Debiopharm
  • Developer Debiopharm; Solid Biosciences
  • Class Ciclosporins
  • Mechanism of Action Cyclophilin inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders
  • Discontinued Duchenne muscular dystrophy; Hepatitis C; HIV infections

Most Recent Events

  • 02 Aug 2019 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in USA, France, Romania, Italy, Hungary, Turkey, Puerto Rico, Australia, Taiwan, Belgium (PO)
  • 02 Aug 2019 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in United Kingdom, Poland, Germany, Sweden (PO)
  • 02 Aug 2019 Discontinued - Phase-II for Hepatitis C in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top